Peanut Allergy Pipeline Insight Report Proffers Clinical Trials Updates, Including Detailed Profiles of Emerging Drugs Along With Companies
10 Aug 2021
Gene TherapyAntibodyBreakthrough TherapyImmunotherapySmall molecular drug
Los Angeles, USA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Peanut Allergy Pipeline Insight Report Proffers Clinical Trials Updates, Including Detailed Profiles of Emerging Drugs Along With Companies
Approximately 10+ key companies are developing therapies for Peanut Allergy treatment. DBV Technologies has its drug candidates in the most advanced stage. The use of new biological compounds is considered to have the potential to treat the disease, which is expected to improve the treatment method in Peanut Allergy patients.
DelveInsight’s “Peanut Allergy Pipeline Insight” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Peanut Allergy pipeline landscapes. It comprises Peanut Allergy pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Peanut Allergy therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Peanut Allergy pipeline products.
Some of the key takeaways from the Peanut Allergy Pipeline Report
Get an overview of pipeline landscape @ Peanut Allergy Clinical Trials Analysis
A Peanut Allergy is a reaction that occurs when the body mistakenly identifies peanuts as harmful substances.
Peanut Allergy Emerging Drugs
DBV is developing the Viaskin technology platform that offers biologically active compounds, including allergens, via intact skin. Viaskin is an electrostatic patch based on Epicutaneous Immunotherapy, or EPIT®, which administers an allergen directly onto the superficial layers of the skin to stimulate the immune system by explicitly targeting antigen-presenting cells without allowing passage of the antigen into the bloodstream. The firm is modifying its skin patch to address the FDA’s adherence concerns, and later this year, DBV will trial the best-performing modified patches in allergy sufferers to work towards FDA approval.
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE), which treats asthma and chronic idiopathic urticaria symptoms by limiting the allergic response Label. It inhibits IgE binding to receptors on mast cells and basophils, blocking the IgE-mediated secretion of inflammatory mediators from these cells. In August 2018, US FDA granted Breakthrough Therapy Designation for omalizumab to prevent severe allergic reactions, including peanut, milk, egg, and others. Genentech and Novartis Pharmaceuticals Corporation are working closely with NIAID and the Consortium of Food Allergy Research to start a potentially pivotal study assessing the efficacy and safety of Xolair in multiple food allergies. It is currently being evaluated in the Phase III stage of development for treating Peanut Allergy patients.
Dupilumab is an IL-4R Antibody that is being developed by Regeneron Pharmaceuticals in collaboration with Sanofi for the treatment of Peanut Allergy. It is currently in the phase II stage of development.
CNP-201 is a biodegradable nanoparticle encapsulating peanut protein. It can treat Peanut Allergy patients by decreasing the requirement for strict peanut avoidance and reducing the potentially severe health risks associated with Peanut Allergy. It is currently in phase I/II stage of development.
VE416 is an orally administered rationally-defined bacterial consortium candidate being developed for the potential food allergy treatment. VE416 comprises clonal human commensal bacterial strains selected for their ability to reduce allergic responses and manufactured under cGMP conditions. It is produced from pure, non-pathogenic clonal bacterial cell banks, which yield a standardized drug product in powdered form. The drug is currently being evaluated in a Phase I/II clinical trial combined with vancomycin to treat patients with Peanut Allergy.
For further information, refer to the detailed report @ Peanut Allergy Pipeline Therapeutics
Scope of Peanut Allergy Pipeline Drug Insight
· Peanut Allergy Therapies Late-stage (Phase III) · Peanut Allergy Therapies Mid-stage (Phase II)· Peanut Allergy Therapies Early-stage (Phase I) · Peanut Allergy Preclinical stage and Discovery candidates · Discontinued and Inactive candidates
· Microbiome modulators; Regulatory T-lymphocyte stimulants· IgE receptor antagonists· Immunomodulators· Interleukin 13 inhibitors; Interleukin 4 inhibitors· Th1 cell stimulants· Immunosuppressants
· Gene therapy · Monoclonal Antibody · Small molecule · Peptides· Polymer
· Intravenous · Parenteral · Oral· Subcutaneous · Intradermal· Topical
· Monotherapy· Combination· Mono/Combination
Key Questions regarding Current Peanut Allergy Treatment Landscape and Emerging Therapies Answered in the Pipeline Report
Table of Contents
Get a customized pipeline report @ Peanut Allergy Drugs Pipeline Report
Other Reports
Browse Blog Posts
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.